Bessemer Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.17M Buy
10,408
+1,843
+22% +$817K 0.01% 566
2026
Q1
$3.83M Buy
8,565
+973
+13% +$454K 0.01% 573
2025
Q4
$3.44M Sell
7,592
-867
-10% -$374K 0.01% 556
2025
Q3
$3.31M Buy
8,459
+994
+13% +$415K 0.01% 411
2025
Q2
$3.32M Sell
7,465
-19
-0.3% -$8.76K 0.01% 402
2025
Q1
$3.63M Buy
7,484
+307
+4% +$143K 0.01% 393
2024
Q4
$2.89M Sell
7,177
-7,613
-51% -$3.53M ﹤0.01% 571
2024
Q3
$6.88M Buy
14,790
+1,949
+15% +$936K 0.01% 358
2024
Q2
$6.02M Buy
12,841
+236
+2% +$102K 0.01% 349
2024
Q1
$5.27M Buy
12,605
+9,193
+269% +$3.89M 0.01% 379
2023
Q4
$1.39M Sell
3,412
-496
-13% -$183K ﹤0.01% 572
2023
Q3
$1.36M Buy
3,908
+457
+13% +$160K ﹤0.01% 551
2023
Q2
$1.22M Buy
3,451
+1,067
+45% +$360K ﹤0.01% 590
2023
Q1
$750K Buy
2,384
+247
+12% +$74.1K ﹤0.01% 643
2022
Q4
$617K Sell
2,137
-725
-25% -$221K ﹤0.01% 677
2022
Q3
$830K Buy
2,862
+814
+40% +$234K ﹤0.01% 621
2022
Q2
$578K Buy
2,048
+119
+6% +$31.9K ﹤0.01% 676
2022
Q1
$504K Buy
1,929
+204
+12% +$48.4K ﹤0.01% 636
2021
Q4
$379K Buy
1,725
+1,314
+320% +$256K ﹤0.01% 703
2021
Q3
$74K Sell
411
-370
-47% -$72.2K ﹤0.01% 990
2021
Q2
$158K Sell
781
-211
-21% -$44.1K ﹤0.01% 841
2021
Q1
$214K Buy
992
+13
+1% +$2.85K ﹤0.01% 740
2020
Q4
$232K Buy
979
+92
+10% +$21.1K ﹤0.01% 714
2020
Q3
$241K Sell
887
-299
-25% -$82.5K ﹤0.01% 684
2020
Q2
$344K Buy
1,186
+516
+77% +$140K ﹤0.01% 1047
2020
Q1
$159K Buy
670
+256
+62% +$58.7K ﹤0.01% 1046
2019
Q4
$91K Sell
414
-178
-30% -$36K ﹤0.01% 1195
2019
Q3
$100K Sell
592
-1,507
-72% -$267K ﹤0.01% 1176
2019
Q2
$385K Sell
2,099
-593
-22% -$104K ﹤0.01% 932
2019
Q1
$496K Buy
2,692
+503
+23% +$92.9K ﹤0.01% 798
2018
Q4
$362K Buy
2,189
+198
+10% +$34.3K ﹤0.01% 830
2018
Q3
$384K Buy
1,991
+134
+7% +$23.9K ﹤0.01% 829
2018
Q2
$315K Sell
1,857
-2
-0.1% -$310 ﹤0.01% 892
2018
Q1
$303K Buy
1,859
+1,416
+320% +$231K ﹤0.01% 922
2017
Q4
$66K Sell
443
-259
-37% -$38.3K ﹤0.01% 1213
2017
Q3
$107K Sell
702
-19
-3% -$2.86K ﹤0.01% 1166
2017
Q2
$93K Sell
721
-2,556
-78% -$308K ﹤0.01% 1193
2017
Q1
$358K Buy
3,277
+3,261
+20,381% +$287K ﹤0.01% 958
2016
Q4
$1K Sell
16
-96
-86% -$7.81K ﹤0.01% 1906
2016
Q3
$10K Sell
112
-289
-72% -$27.3K ﹤0.01% 1527
2016
Q2
$34K Sell
401
-37
-8% -$3.2K ﹤0.01% 920
2016
Q1
$34K Sell
438
-600
-58% -$54.3K ﹤0.01% 969
2015
Q4
$131K Buy
1,038
+116
+13% +$14K ﹤0.01% 798
2015
Q3
$96K Sell
922
-10
-1% -$1.28K ﹤0.01% 842
2015
Q2
$115K Buy
932
+53
+6% +$6.68K ﹤0.01% 827
2015
Q1
$103K Buy
879
+29
+3% +$3.48K ﹤0.01% 820
2014
Q4
$101K Buy
+850
New +$95.7K ﹤0.01% 801
2014
Q3
Sell
-221
Closed -$21K 1399
2014
Q2
$21K Sell
221
-315
-59% -$22.1K ﹤0.01% 1002
2014
Q1
$39K Buy
536
+436
+436% +$34.5K ﹤0.01% 897
2013
Q4
$8K Sell
100
-91
-48% -$6.34K ﹤0.01% 1115
2013
Q3
$15K Buy
191
+141
+282% +$11.2K ﹤0.01% 993
2013
Q2
$4K Buy
+50
New +$3.68K ﹤0.01% 1182

Other funds holding VRTX

Bessemer Group's VRTX Position: Q2 2026 in Review

Bessemer Group increased its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, buying an estimated $817K and bringing the position to 10,408 shares worth $5.17M. The position accounts for 0.01% of the portfolio, ranked #566.

Bessemer Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.88M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bessemer Group held 10,408 shares of Vertex Pharmaceuticals worth $5.17M as of Q2 2026.
  • Bessemer Group bought 1,843 Vertex Pharmaceuticals shares in Q2 2026, an estimated $817K.
  • Vertex Pharmaceuticals made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #566 holding.
  • Bessemer Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bessemer Group's Vertex Pharmaceuticals position peaked at $6.88M in Q3 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.